Introduction
Rheumatoid arthritis (RA) is an autoimmune disease characterised by peripheral, symmetric polyarthritis with potential for joint deformity that can cause functional disability, premature mortality and reduced quality of life. It is estimated that 0.3-1.0% of the population worldwide is affected by RA, which is most frequently observed in developing countries and in women. 1 The treatment of RA patients combines educational, preventive and non-pharmacological interventions with pharmacological treatment and surgical procedures. First-line therapy includes the early use of a synthetic disease-modifying anti-rheumatic drug (DMARD), such as methotrexate (MTX), which is the drug of choice. 2 However, only 20-40% MTX monotherapy-treated patients show a satisfactory clinical response. 3 Drug combinations are a valid strategy in nonresponsive patients, which may include the addition of another synthetic DMARD or the biological DMARD agents, such as tumour necrosis factor ␣ blockers (anti-TNF␣). 4 Infliximab (IFX) is a chimeric monoclonal antibody (murine) of the anti-TNF␣ class that represents approximately 40% of biological agent prescriptions. 5, 6 Second-line treatment strategies show similar rates of success and the choice among them is based primarily on the presence or absence of a poor prognosis and in the disease activity. 4, 7 The benefits of adding sulfasalazine (SSZ) and hydroxychloroquine (HCQ), [8] [9] [10] [11] leflunomide 12 or cyclosporin 13 to MTX therapy have been demonstrated. The IFX + MTX combination has been assessed in numerous systematic reviews [14] [15] [16] [17] [18] [19] but their control groups included only placebo or MTX treatment. Key issues, including the effect of disease duration, dose and patient profile, were not sufficiently addressed in most of these reviews.
With this systematic review and meta-analysis we aimed to assess the efficacy and safety of IFX + MTX compared to MTX in monotherapy or in combination with other synthetic DMARDs considering treatment-relevant clinical outcomes.
Methods
A systematic review with meta-analysis was performed according to the Cochrane Handbook for Systematic Reviews of Interventions. The results were reported according to the "Preferred Reporting Items for Systematic Reviews and Meta Analyses: The PRISMA statement". 20 This review is part of another project entitled "Evaluation of the effectiveness and safety of biological agents adalimumab, etanercept, infliximab and rituximab used in the treatment of rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis, Brazil and Minas Gerais", which was performed by the Research Group on Pharmacoepidemiology and Research Group on Health Economics at the UFMG.
Search strategy
The online search was performed in EMBASE (until April 2012), CENTRAL (until June 2012), PubMed (until July 2012) and LILACS (until October 2012) databases. Different combinations of keywords, mesh terms and filters were applied, and the full search strategy for each database was provided online in Appendix 1. We performed a manual search in the references of all included studies and previously published systematic reviews. We also searched the grey literature in the Annals of the American College of Rheumatology (ACR, 2011 (ACR, , 2012 
Eligibility criteria
We included phase III RCTs that evaluated RA patients diagnosed according to the American College of Rheumatology (ACR) criteria 1987 21 regardless of disease duration. We considered eligible studies comparing IFX + MTX versus MTX as a monotherapy or in combination with other synthetic DMARDs. The minimal follow-up period was two months.
The following exclusion criteria were applied: studies that were not performed exclusively on RA patients; changes in therapy over time; drug-conversion studies; pilot studies; editorials/reviews/letters/comments; and studies published in languages other than Portuguese, Spanish or English.
Study selection
Two reviewers independently evaluated the titles, abstracts and full text of all identified studies to assess their eligibility. A third reviewer resolved disagreements.
Assessment of methodological quality and risk of bias
Methodological quality was assessed using the modified Jadad scale, 22 which evaluates randomisation, blinding and loss to follow-up using seven dichotomous questions that are worth one point each. Studies with inadequate randomisation lose one point. The final score ranges from 0 to 6: 0-2 indicate a low-quality study, 3 or 4 indicates adequate quality, and 5 or 6 indicates high quality. The risk of bias was assessed using the Cochrane Collaboration tool, 23 which considers six dimensions: random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data and selective reporting of outcomes. The study was classified as having low risk of bias when all criteria were reported and were adequate, a high risk of bias when at least one of the criteria was inadequate, and an uncertain risk of bias when one or more items were not reported. The inter-rater reliability was measured using the Kappa statistic according to Landis and Kock 24 and calculated using SPSS ® 17.0 software. Inter-rater reliability was substantial for the modified Jadad scale (0.70 ± DP 0.73) and moderate for the risk of bias assessment (0.55 ± 0.78).
Data collection
Two independent reviewers collected data on study design, methodological quality, risk of bias, patient profile, efficacy and safety outcomes using an electronic form that was designed in Excel ® 2007. A consensus resolved all disagreements.
The primary outcome was the measurement of ACR20, which is defined as 20% improvement in swollen joints and joint pain in combination with a 20% improvement in three of five criteria: patient's global assessment of pain; patient's global assessment of disease activity; physician's global assessment of disease activity; patient's assessment of physical function; and C-reactive protein levels. 25 Secondary outcomes included the ACR50 and ACR70, clinical remission (defined as a DAS28 [Disease Activity Score 28] < 2.6), radiographic data, loss to follow-up and adverse events.
Statistical analysis
A random effects model was used for all meta-analyses due to the clinical heterogeneity of the included studies. Relative risk (RR) was used as a measure of treatment effect, and it was calculated using the Mantel-Haenszel method for binary data. Mean differences and the inverse variance method were used for continuous data. Confidence intervals of 95% were presented for both measures. Heterogeneity was assessed using the 2 test for heterogeneity and the I 2 index and was considered statistically significant when p value was lower than 0.10 and I 2 value higher than 40%. 26 We identified the source of heterogeneity through a sensitivity analysis, in which studies were removed from the meta-analysis one by one to investigate possible causes related to patients and study characteristics. Subgroup analysis was also performed to evaluate the effects of pre-treatment, study length, dosage and the IFX administration regimen. In the meta-analysis we included results from the longest available follow-up, unless indicated otherwise. We used Review Manager ® software version 5.1 for statistical tests (Copenhagen: The Cochrane Collaboration, 2011).
Results
We identified 5782 articles, of which 249 were considered for full reading and 74 articles were selected. A total of 11 articles, representing multiple publications of nine studies, evaluated IFX and met the inclusion criteria for this review (Fig. 1) . We found one completed phase III clinical trial with unpublished results (Table 1 , online resource). We have not found any thesis or dissertations. Abstracts found in the annals of meetings had their respective full articles collected by manual search. The characteristics of the nine included trials are presented in Table 1 . The studies were published between 1998 and 2012, and the follow-up periods ranged from 14 to 104 weeks. Patients profile included individuals previously treated with DMARDs, not treated with MTX or those that had insufficient responses to MTX.
Most studies defined active RA by the presence of six or more swollen joints and six or more tender joints in combination with the additional criteria of morning stiffness, C-reactive protein levels and erythrocyte sedimentation rates. ASPIRE 27 and ATTEST 28 (4) 
Methodological quality and risk of bias
Nine trials were classified as randomised, but only two of these studies reported the methods of randomisation. 27, 35 The Jadad scale score was generally good (ranging from moderate to high). The pharmaceutical industry funded six studies. 27, 28, 30, 31, 34, 35 We identified a potential source of bias in three trials, 30, 31, 33 and only one study 35 was classified as low risk of bias (Table 2) .
ACR response

Infliximab standard dose (3 mg/kg every eight weeks) per follow-up period
Eleven studies were included in this analysis. Six of them included 1470 patients and presented results of up to 30 weeks of follow-up, [28] [29] [30] 32, 34, 35 four studies with 1086 patients presented results of 52 weeks 27, 30, 31, 36 and one study of 258 patients presented results of 104 weeks. 3 Patients who received combination therapy with IFX showed a better ACR response than patients treated with MTX alone or in combination with DMARDs until 30 and 52 weeks of treatment. However, no significant difference between groups was observed after 104 weeks of follow-up. The heterogeneity of ACR20 and ACR50 was significant and moderate for the 30 weeks of follow-up studies (Table 3 ). Heterogeneity at 52 weeks of follow-up was assessed using the stratification between MTX-naive patients and patients with insufficient responses to MTX (see Section "Heterogeneity assessment and subgroup analysis").
Infliximab standard dose per patient profile
The patient's previous treatments, regardless of follow-up period, revealed that the IFX + MTX combination achieved better results than synthetic DMARDs in patients who had previously failed to MTX treatment, compared to MTX-naïve patients (Table 3) .
Infliximab standard dose according to disease duration
Combination therapy with IFX showed better ACR responses than MTX alone or in combination with synthetic DMARDs in patients with established RA. This result was not observed in patients with early RA (Table 3) .
High-dose infliximab
Patients that used IFX regimens with doses higher than 3 mg/kg or in shorter intervals showed better ACR responses than patients treated with MTX alone or in combination. Metaanalysis of high-dose IFX versus standard dose of 3 mg/kg every eight weeks did not show difference in ACR20 and ACR50 outcomes within 54 weeks of follow-up. Despite being statistically significant, difference in ACR70 response was boarder line favouring IFX high-doses (Table 3) .
Clinical remission
Two studies assessed clinical remission at 28 28, 34 and 54 weeks of follow-up 27, 30 
Radiographic progression
A meta-analysis of three studies 3,27,36 revealed lower radiographic progression in patients who were treated with IFX + MTX at a standard dose than in patients who were treated with other synthetic DMARDs at 52 and 104 weeks. Statistically significant differences were observed in patients with an insufficient response to MTX and treatment-naive patients (Fig. 2) .
Withdrawals
A meta-analysis of five studies, 3 
U, unclear risk of bias; L, low risk of bias; H, high risk of bias. 84 [0.71, 4.79]) . However, the heterogeneity of serious infections was moderate and significant (68%; 0.04), the study ASPIRE 27 being the source of this heterogeneity. The risk of serious infections became higher in patients who received high-dose IFX than patients who received the standard IFX dose when the ASPIRE study was excluded, and no significant heterogeneity was observed (RR = 3.07 [1.42; 6 .64]).
Heterogeneity assessment and subgroup analysis
The heterogeneity of ACR20 and ACR50 was significant and moderate for the studies with up to 30 weeks of followup (Table 3) . Heterogeneity became non-significant and the results remained favourable to IFX + MTX (1.74 [1.32; 2.29]) when the ATTRACT 35 and START 34 studies were excluded from the ACR20 meta-analysis of 30 weeks. Heterogeneity became non-significant and the results still favoured the group receiving IFX + MTX (1.74 [1. 32; 2.29]) when the START study 34 was excluded from the ACR50 meta-analysis of 30 weeks. No reasonable explanation for the source of heterogeneity could be established. The cause of heterogeneity of ACR analysis at 52 weeks was the difference in patient profile with respect to previous experience with DMARs. Therefore, we conducted a subgroup analysis, in which ACR20 showed no statistical significance between the groups who received IFX + MTX or DMARDs in patients with an insufficient response to MTX 
Discussion
This systematic review and meta-analysis included nine randomised controlled clinical trials and one ongoing study, and showed superior results of efficacy as evaluated by ACR and DAS28, and of radiographic progression for IFX + MTX compared to MTX monotherapy or in combination with other DMARDs, regardless of disease duration, dose and patient profile.
The efficacy of the IFX + MTX regimen was assessed from 14 weeks of treatment 32 to 104 weeks 3 in patients with an insufficient response to MTX and in MTX-naive patients. IFX + MTX use began early after RA diagnosis 30, 31 or after 10 years of disease duration 32, 35, 36 on average. The therapeutic regimen was variable and included the administration of 3 or 10 mg/kg IFX every four or eight weeks 33, 35, 36 or 6 mg/kg IFX every eight weeks. 27 The control group included placebo + MTX or a combination of synthetic DMARDs.
These differences affected the size and direction of the effect, which favoured IFX + MTX especially during shorter periods of follow-up in patients with established RA and an insufficient response to MTX. These results support the treatment with synthetic DMARDs, reserving the IFX + MTX regimen for cases of a failure of the first-line regimen. This approach is corroborated by Du Pan et al., 37 who performed a systematic review that specifically evaluated patients with early RA and recommended the use of IFX + MTX for cases with rapid radiographic progression, insufficient response to MTX or other clinical and biological signs of aggressive disease, since there is no robust evidence that supports the efficacy, safety and cost of the early use of IFX.
The results of efficacy and safety also encourage the use of the recommended standard regimen of 3 mg/kg IFX at weeks 0, 2 and 6 and then every eight weeks in combination with MTX, instead of increased dose or shorter intervals of IFX administration, as described in individual studies. 4, 7 Clinical remission favoured the use of IFX + MTX after 24 and 54 weeks of treatment and the ACR response after 52 weeks. However, the high heterogeneity of the analysis of ACR20 and ACR50 for up to 30 weeks of treatment and the lack of effect of ACR20 at 52 weeks in the subgroup analysis by past DMARD exposure were notable. Wiens et al. 18 also reported inconsistent results in the ACR20 and 50 responses after 30 weeks, and considered the high number of patients who achieved the therapeutic response in the test and control groups on the START 34 study as a possible explanation. The ACR20 response may be more sensitive to the use of some treatments because it is less strict. However, differences between treatments became more evident with more strict ACR responses because in this case these responses were directly related to the efficacy of the biological agent use.
Furthermore, only the SWEFOT study 3,31 assessed efficacy outcomes for up to 104 weeks of follow-up, and this study reported no difference in the ACR responses between IFX + MTX and DMARD combination groups. This affected also the meta-analysis of our study, because when it was excluded the result of efficacy outcomes was favourable for the IFX + MTX. In contrast, the prevention of radiographic progression using IFX + MTX was confirmed, despite the control group (i.e., with DMARD combination or MTX monotherapy).
Withdrawals due to adverse events were especially affected by the exclusion of the SWEFOT study. 3, 31 With the exclusion of this study the analysis became statistically significant favouring IFX + MTX. This result was expected because the addition of a higher number of drugs to a therapeutic regimen increases the probability of adverse events and decreases the differences between strategies. Other systematic reviews that did not include this study also reported a greater loss to followup as a result of adverse events in the IFX + MTX group. 16, 18 Considering withdraw due to adverse events according to patients' past experience with DMARDs, the results of our meta-analysis showed higher risk of loss in the IFX + MTX group for MTX-naive patients, but not for patients with an insufficient response to MTX, as reported by Chen et al. 15 These results suggest that previously treated patients exhibit a higher tolerance to adverse events. No differences in safety were observed in this or previous systematic reviews, 15, 18, 19 but other evidence sources have reported that the use of anti-TNF␣ increases patients' risk of developing tuberculosis (TB) and other infections. [38] [39] [40] An evaluation of the biological products database of the Spanish Society of Rheumatology revealed incidence rates of 1113 per 100,000 in 2001, which was significantly higher than national rates. 38 A meta-analysis of safety from observational studies 40 related an increased risk of infections of approximately 40% for RA patients who were treated with anti-TNF␣ (RR = 1.37 [1.18; 1.60]). These risks support the use of TB screening for all patients who might receive anti-TNF␣ treatment, and these patients should be followed using new tests for the signals and symptoms of infections, especially during the first year of treatment. 7, 41 Regarding the comparison of high-dose IFX and the standard dose of 3 mg/kg every 8 weeks, we did not find significant differences in ACR outcomes after 54 weeks of follow-up. Therefore, the lower dose of 3 mg/kg IFX every eight weeks was as effective as the other doses in isolated studies 32, 34, 35 and in the meta-analysis of this review. However, the results of the meta-analysis on serious infections showed significant heterogeneity. The ASPIRE 27 study, which included MTX-naive patients, was excluded, and the risk of infections became higher with high doses of IFX + MTX, showing that MTX-naive patients may be more susceptible to infections. Therefore, the group that received high doses of IFX had high infection rates compared to the standard dose IFX group. These results were consistent with Aaltonen et al. 19 and Alonso-Ruiz et al. 16 who reported no differences in efficacy between high and standard doses of IFX. However, no difference in safety between the dose regimens was described, 19 although this study did not analyse heterogeneity or perform a subgroup analysis by patient DMARD exposure. An IFX induction regimen using 10 mg/kg is not indicated by the manufacturer, and it is discouraged by the results of clinical trials and this systematic review, since it provides no additional benefits. Besides, this strategy can increase the risk of infections compared to placebo + MTX group. 34, 35 One RCT that was not included in our systematic review because of the dose escalation analysed the increase in IFX dose from 3 to 5 mg/kg every 8 weeks and revealed no additional benefit to the primary outcome (DAS28 after 28 weeks) or secondary outcomes (e.g., number of swollen and tender joints, C-reactive protein and erythrocyte sedimentation rate) within 52 weeks. Furthermore, an increase in the incidence of adverse events was observed, but these adverse events did not include serious adverse events or serious infections. 42 Ollendorf et al. 43 also demonstrated that patients using IFX increased the dose more frequently over shorter periods of time than patients using etanercept and adalimumab (32.1%, 8.5% and 4.7%, respectively). Consequently, the cost of IFX treatment was approximately 30% higher than other anti-TNF␣ agents. These results suggest that increasing IFX dose in patients who do not adequately respond to the standard dose of 3 mg/kg IFX every eight weeks in combination with MTX is not the best strategy. 42, 44 Limitations A random effects model was used, and the results of the subgroup analyses lost part of its inference value due to the clinical heterogeneity of trials in the evaluated outcomes, patient profile, period of follow-up, dose and administration period. However, the results were consistent with the literature, and although not entirely reflective of reality, they demonstrate the direction of the effect. Other limitation is that only three of the published RCTs were not funded by the pharmaceutical industry. Studies funded by the pharmaceutical industry are more likely to report favouring outcomes to their products 45 and therefore, the results of these studies should be interpreted cautiously. Because of that, the assessment of risk of bias became more pertinent, and only one study in this review was classified as a low-risk of bias in all assessed domains. Also, we could not assess the publication bias of the outcomes because the recommended number of clinical trials to perform this analysis with robustness is 10 studies. However, we conducted the manual search and search through the grey literature to minimise this effect. Evidence on the IFX + MTX regimen versus MTX is well established, but other types of comparison must be explored. Only one published study 3, 31 assessed the regimen INF + MTX versus a DMARD combination. Because of that, this systematic review could not establish the best strategy for patients in whom first-line therapy fails. Clinical trials that compare the efficacy of IFX + MTX to combinations of DMARDs are required to cover this knowledge gap.
Implications for clinical practice
The use of IFX + MTX promoted radiographic and clinical benefits that were less significant in early RA patients, which suggests that early treatment with any synthetic DMARD is more important than early treatment using a biological agent. The combination of IFX + MTX may be a better strategy for the prevention of radiographic progression than MTX alone. The choice between INF + MTX over combination DMARDs should consider their ability to reduce functional loss over time (i.e., radiographic progression) balanced with the small clinical differences that are observed over long periods of follow-up, and the higher cost of anti-TNF␣ treatment.
Conclusions
IFX + MTX therapeutic regimens showed better results of clinical efficacy evaluated by ACR and DAS28 than MTX monotherapy or combined DMARDs, regardless of disease duration, dose and patient past experience with DMARD. The efficacy of IFX + MTX was more evident in shorter periods of follow-up, patients with established RA and patients with insufficient response to MTX. Radiographic progression was averted in longer follow-up periods. The lowest dose, 3 mg/kg IFX every eight weeks, was as effective as the other IFX doses. The data on safety suggest that increases in IFX doses were related to an increased incidence of infections, and therefore should not be used. 
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